RXRX vs SDGR
RXRX: Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug discovery and development process. SDGR: Physics-based computational platform that accelerates drug discovery and materials science by predicting molecular properties with high accuracy, enabling faster, cheaper, and more successful drug development.
Side-by-side fundamentals
| Metric | RXRX | SDGR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.98 | $15.03 | |
| Market cap as of 2026-07-23 | $1.6B | $1.1B | |
| Net margin as of 2026-07-23 | -842.9% | -40.6% | SDGR higher |
| Gross margin as of 2026-07-23 | +7.2% | +55.3% | SDGR higher |
| Operating margin as of 2026-07-23 | -881.3% | -64.7% | SDGR higher |
| ROE as of 2026-07-23 | -54.3% | -30.9% | SDGR higher |
| ROA as of 2026-07-23 | -40.6% | -15.3% | SDGR higher |
| Debt / equity as of 2026-07-23 | 0.02 | 0.00 | SDGR lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.1% | +10.6% | RXRX higher |
| Revenue CAGR (3y) SEC XBRL | +23.3% | +12.2% | RXRX higher |
| Beta as of 2026-07-23 | 1.08 | 1.65 | |
| 1-year return as of 2026-07-22 close | -54.4% | -34.0% | SDGR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.